COVID-19: Antiviral drug Molnupiravir blocks virus transmission within 24 hours, claims Study
"This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission. MK-4482/EIDD-2801 could be game-changing," said study author Richard Plemper from GSU.;
Advertisement
New York: Researchers have discovered that the treatment of SARS-CoV-2 infection (Covid-19) with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses the virus transmission within 24 hours.
According to the study, published in the journal Nature Microbiology, the research team from Georgia State University (GSU) originally discovered that the drug is potent against influenza viruses.
"This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission. MK-4482/EIDD-2801 could be game-changing," said study author Richard Plemper from GSU.
Because the drug can be taken by mouth, treatment can be started early for a potentially three-fold benefit: inhibit patients' progress to severe disease, shorten the infectious phase to ease the emotional and socio-economic toll of prolonged patient isolation and rapidly silence local outbreaks,
Read also: Pfizer seeks DCGI emergency use authorisation for COVID vaccine in India
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.